Users Online: 222
Home Print this page Email this page
Home About us Editorial board Search Browse articles Submit article Ahead of Print Instructions Subscribe Contacts Special issues Login 
Year : 2015  |  Volume : 4  |  Issue : 1  |  Page : 257

Pulsed dye laser and topical timolol gel versus Pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial

1 Department of Dermatology; Skin Diseases and Leishmaniasis Research Center, Tehran University of Medical Sciences, Tehran; Isfahan University of Medical Sciences; Isfahan, Iran
2 Department of Dermatology, Tehran University of Medical Sciences, Tehran; Isfahan University of Medical Sciences; Isfahan, Iran
3 Department of Dermatology; Isfahan University of Medical Sciences; School of Medicine, Tehran University of Medical Sciences; Tehran, Iran
4 Skin Diseases and Leishmaniasis Research Center; Skin and Stem Cell Research Center; Tehran University of Medical Sciences, Tehran, Iran
5 Isfahan University of Medical Sciences; Department of Epidemiology and Biostatistics, School of Public Health, Isfahan, Iran

Correspondence Address:
Atefeh Sadat Kamali
Department of Dermatology, Isfahan University of Medical Sciences, Al-Zahra Hospital, Soffeh Blvd, Isfahan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2277-9175.170682

Rights and Permissions

Background: Infantile hemangioma (IH) is the most common tumor during infancy that usually appears as macular and gradually becomes a plaque or tumor. Approximately, 20% of all IH cases results in adverse effects and the Pulsed dye laser (PDL) 585 nm is a vascular laser leading to selective the micro vascular damage. Results of studies on non-selective B-blockers (e.g., timolol) indicate their effectiveness in preventing hemangioma growth. The aim of this study is a comparison of PDL plus timolol and PDL in the treatment of IH. Materials and Methods: This double-blind study was carried out on 30 infants (1-12 months old) and the patients were divided into two groups. Group A was treated with the four sessions PDL and the timolol gel 0.05% and Group B with PDL. Results: There were no differences in the mean age of patients for the diagnosis of hemangioma (Group A: 32.69 ± 24.64 days, Group B: 25.69 ± 21.16 days, P = 0.39) and the mean age at the start of the treatment (Group A: 148.125 ± 85.88 days, Group B: 146.25 ± 60.87 days, P = 0.94). There were a statistical difference in the mean of lesion size reduction (Group A: 17.62 ± 6.97 cm and Group B: 12 ± 5.71 cm, P = 0.018), mean percentage change in size mean (Group A: 71079 ± 23.41% and Group B: 54.59 ± 25.46%, P = 0.050) visual analog scale (Group A: 7.19 ± 1.51, Group B: 5.62 ± 1.78, P = 0.012) after treatment. There was no correlation between the time of beginning the treatment and the results (P = 0.857). Conclusions: Application of timolol with PDL is accompanied by the highest efficacy, cost benefits and the short time of treatment.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded837    
    Comments [Add]    
    Cited by others 13    

Recommend this journal